Fully integrated PET/MR imaging holds great promise as a novel hybrid imaging modality in oncology and might offer advantages to PET/CT in many instances, especially because of the superior softtissue contrast of MR imaging, compared with CT. However, lung metastases are a frequent finding in oncologic patients, and for imaging of the lung CT is still the modality of choice. Thus, we prospectively evaluated differences in quality, detection rate, size, and radiotracer uptake of pulmonary lesions in 18 F-FDG PET/CT and PET/MR imaging. Methods: Institutional review board approval and informed consent were obtained. Forty patients (23 men, 17 women; mean age ± SD, 53.2 ± 13.1 y) underwent a single-injection dualimaging protocol with 18 F-FDG PET/CT and PET/MR imaging. Pulse sequences for the lung included T1-weighted VIBE (volumetric interpolated breath-hold examination) Dixon for attenuation correction and contrast-enhanced VIBE pulse sequences. All patients underwent a diagnostic CT of the chest in deep inspiration, which also served as a standard of reference. Two masked readers assessed in consensus all images randomly concerning quality, detection, standardized uptake value (SUV), and size of pulmonary nodules. Correlations were performed using linear correlation. Results: Overall, 47 pulmonary lesions (mean size ± SD, 10.0 ± 11.4 mm; range, 2-60 mm) in 25 of 40 patients were detected. The PET datasets of PET/MR imaging and PET/CT revealed 22 of 47 pulmonary lesions with focal 18 F-FDG uptake. SUVs of lung lesions in PET/MR imaging and PET/CT correlated significantly (R 5 0.9; P 5 0.0001) and showed no significant difference (mean SUV PET/MR imaging, 6.3; PET/CT, 5.1; P 5 0.388). There was a significantly lower image quality comparing Dixon and VIBE sequence with CT whereas PET from PET/CT and PET from PET/MR imaging showed the same results (2.8). Dixon images detected 15 of 47 lung lesions whereas VIBE images detected 32 of 47 lesions, respectively. The detection rates for small lung lesions less than 1 cm in diameter (n 5 33) of MR imaging was significantly lower, with a detection rate of 9 of 33 for the Dixon sequence and 15 of 33 for the VIBE sequence (P , 0.0001 for VIBE and Dixon sequence). There was a high correlation of pulmonary lesion size of CT versus VIBE (R 5 0.97). Conclusion: PET image quality and detection rate of 18 F-FDG-positive lung lesions in PET/MR imaging is equivalent to PET/CT despite differences in attenuation-correction techniques. Additionally, a high linear correlation coefficient in the SUVs for the PET images from PET/CT and PET/MR imaging was found. The detection rate of lung lesions can be significantly improved by adding a diagnostic contrast-enhanced VIBE sequence to the PET/MR imaging protocol. However, the detection rate of small lung lesions is still inferior, compared with PET/CT with diagnostic CT of the chest. Pul monary lesions are a common incidental finding in imaging studies although their evaluation is complex and still remains a diagnostic challenge. Advances in CT, MR imaging, and PET have improved their characterization, helping to differentiate benign and malignant lesions, which is important for the future prognosis of a patient (1). Several studies confirmed that 18 F-FDG PET is an accurate method for characterizing pulmonary lesions, with an overall sensitivity of 96.8% and a specificity of 77.8% (2). The development of integrated PET/CT as a combination of anatomic and metabolic imaging has also demonstrated an excellent performance in classifying pulmonary lesions (3). However, in PET/CT, pulmonary nodules smaller than 10 mm in diameter are often false-negative when looking at 18 F-FDG uptake only and in this case can be detected on the corresponding CT part only (2,4). CT is still the method of choice for detecting small lung lesions, because MR imaging of the chest is limited by low proton densities of the lung parenchyma and fast transverse magnetization decay (5-7). With the development of PET/MR imaging whole-body staging examinations in oncology, the value of PET/MR imaging, compared with PET/CT, with respect to the detection of lung lesions is of specific interest. Recent studies in a small number of patients suggest the feasibility of whole-body PET/MR imaging in the assessment of lung cancer, with similar lesion-characterization and tumor-stage-comparing ability between PET/CT and PET/MR imaging (8). However, this study dealt with primary lung cancer staging and did not analyze the performance of PET/MR imaging for the evaluation of lung metastases, which might be substantially smaller. Moreover, the techniques for attenuation correction of PET data in PET/MR imaging are different from those in PET/CT. However, quantitative analysis of tracer uptake using the standardized uptake value (SUV) is essential for correct analysis of PET tracer distribution (9-13). Currently, in the commercially available whole-body fully integrated
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Thus, the purpose of our study was 2-fold: first, to compare the performance of PET/MR imaging including diagnostic MR imaging sequences for detecting lung lesions, compared with PET/CT, in oncologic diseases; second, to analyze the significance of the different attenuation-correction techniques in PET/MR imaging, compared with PET/CT, for the evaluation of 18 F-FDG-positive lung lesions.
MATERIALS AND METHODS

Patient Population
In this study, 40 randomly selected patients (23 men, 17 women; mean age 6 SD, 53.2 6 13.1 y; age range, 18-79 y), routinely referred to our institute for clinical 18 F-FDG PET imaging for staging or follow-up of malignant or suspected malignant disorders, were included. Patients with the following medical characteristics were recruited between July 2011 and August 2012: bronchial carcinoma, n 5 2; breast cancer, n 5 4; thyroid cancer, n 5 5; lymphoma, n 5 3; head and neck cancer, n 5 20; carcinoma of unknown primary, n 5 1; testicular cancer, n 5 1; adrenal gland cancer, n 5 1; primary liver tumor, n 5 1; rectal cancer, n 5 1; and liver hemangioendothelioma, n 5 1.
The local institutional review board approved this study. Written informed consent was obtained from all patients. Inclusion criteria were informed consent, ability to undergo another scan after the PET/CT examination, and clinical indication for an 18 F-FDG PET/CT scan. Exclusion criteria were pregnancy, age below 18 y, and contraindications for MR imaging examinations (e.g., magnetic metal implants, pacemakers).
Imaging Protocol
All subjects underwent a single-injection dual-imaging protocol. After completion of the PET/CT scan, patients were subsequently positioned on the PET/MR imaging scanner with the smallest possible temporal delay.
PET/CT images were acquired according to standard clinical protocols, as previously reported (10) on a Biograph Sensation 64 PET/CT scanner (Siemens Medical Solutions) (18) . Patients fasted for at least 6 h before scanning, and blood glucose levels were measured just before injection to ensure a value below 150 mg/dL. Patients were injected with 383 6 35 MBq of 18 F-FDG intravenously depending on their body weight, and the acquisition was started at 87 6 35 min after injection, moving from the pelvis to the head. Acquisition time was 2 or 3 min per bed position, with 5-6 bed positions (each 21 cm) covering the trunk of the patients. For attenuation-correction purposes and anatomic correlation, a low-dose CT scan (120 keV, 20 mAs, no intravenous contrast) was acquired in shallow expiration. When clinically indicated, a diagnostic CT (120 kV, 240 mAs, 0.5 s per rotation, 5-mm slice thickness, portal venous phase 80 s after the injection of 80-120 mL intravenous contrast agent [Imeron 300; Bracco Imaging Deutschland GmbH]) was performed. In these cases, the diagnostic CT was used for attenuation correction. For evaluation of the lungs, a separate low-dose CT of the chest in deep inspiration was performed in all patients (25 mAs, 120 kV, 0.5 s per rotation, 5-mm slice thickness). CT images of the chest were reconstructed with a standardized window setting for lung parenchyma visualization (window level, 2450 Hounsfield units [HU] ; window width, 1,800 HU) using a sharp convolution kernel. Nonoverlapping images were reconstructed with a slice thickness of 5 mm.
All PET/MR imaging examinations were performed using a fully integrated whole-body hybrid PET/MR imaging system (Biograph mMR; Siemens Healthcare). The technical specifications have been described previously (19) (20) (21) .
On average, PET/MR imaging was started 125 6 25 min after injection. The combined imaging protocol was as follows: after obtaining a localizer MR image to define the bed positions, combined PET/MR imaging was initiated with 3-5 bed position at 4-min acquisition times per bed position. First, a coronal 2-point Dixon 3-dimensional VIBE T1-weighted MR image sequence was acquired in each bed position in shallow expiration, which was used for the generation of attenuation maps (9) . The technical parameters for this sequence are summarized in Table 1 . To minimize artifacts from incomplete breath-hold, a centric k-space acquisition was chosen (22) . Together with the start of this Dixon MR image sequence, the PET acquisition started simultaneously in the same bed position, thus ensuring optimal temporal and regional correspondence between MR imaging and PET data. In the thorax and abdomen region, the MR images were acquired during breath-hold in end-expiratory phase. An additional fat-suppressed contrast-enhanced 3-dimensional VIBE pulse sequence was performed over the lung in deep inspiration with the sequence parameters summarized in Table 1 .
Data Processing and Image Reconstruction
Identical reconstruction and correction algorithms for PET data obtained on the PET/CT and on the PET/MR imaging scanner were used. For both modalities, emission data were corrected for randoms, dead time, scatter, and attenuation. A 3-dimensional ordered-subset expectation maximization iterative reconstruction algorithm was applied, with 3 iterations and 21 subsets, 4 mm in full width at half maximum gaussian smoothing, and a zoom of 1. Attenuation maps were obtained from the CT data by bilinear transformation, as implemented in the postprocessing software of the PET/CT scanner and used for attenuation correction of the PET/CT data, as previously described (11) .
For a subset of patients with 18 F-FDG-positive lesions, the PET data from PET/MR imaging were reconstructed using the HUs from normal lung from the corresponding CT data of the patient instead of the fixed m value of 224 normally used in PET/MR imaging for the lungs.
MR Imaging-Based Attenuation Correction
For attenuation correction of the PET data from the PET/MR imaging, attenuation maps were generated as recently published (9, 10) . The lungs were identified by connected-component analysis of the air in the inner part of the body. By application of a morphologic closing filter, virtual air artifacts induced by the absence of an MR imaging signal in cortical bone, heart, and aorta (because of blood flow) were corrected (12) .
Image Analysis
Images were analyzed by 2 readers (1 nuclear medicine physician and radiologist and 1 radiologist) masked to the patient history. The different datasets of each patient (CT, T1-weighted VIBE Dixon sequence, T1-weighted VIBE fat-saturated sequence, PET of PET/MR imaging, and PET of PET/CT) were evaluated with at least a 2-wk interval. The entire rating procedure was performed on a dedicated workstation using software (Syngo MMWP [workstation] and Syngo TrueD [software]; Siemens Medical Solutions).
The 18 F-FDG PET data from both modalities and CT, Dixon, and VIBE sequences were rated for every patient with regard to overall image quality: 0, non-diagnostic image quality; 1, low image quality (distinct artifacts, strong image noise); 2, satisfying image quality (little artifacts, moderate image noise); and 3, excellent image quality (no artifacts, low image noise).
Subsequently, in a first step, the detection rate of pulmonary lesions (benign or malignant) in the 2 different MR image sequences (Dixon and VIBE sequences) and both PET datasets (including both the non-attenuation-corrected and the attenuation-corrected PET) was assessed (0, absence of a lung lesion; 1, presence of one or several lung lesions), with CT being the standard of reference. If a lung lesion was found, its dignity was rated on a 3-point-scale (1, most likely unspecific/ benign; 2, indeterminate; and 3 suggestive of malignancy) in each morphologic and both PET datasets. In addition, in every morphologic dataset its size in millimeters was measured. For rating of the PET/CT data, PET images were screened for any suspected focal uptake. The standard of reference was based on the CT scan including both past and follow-up examinations as well as medical history and all other clinical information.
Quantitative Assessment
For quantitative comparison of the PET and CT data, an SUV analysis of tracer uptake in the suspected lesions and in the right and left normal lung was performed. Volumes of interest were placed over matching corresponding 18 F-FDG images of suspected lung lesions. To calculate SUVs, an isocontour volume of interest including all voxels above 50% of the maximum was created covering the whole lesion volume. Within all volumes of interest, mean SUV (SUV mean ) and maximum SUV (SUV max ) were measured. For areas of normal lungs, regions of interest (3-cm diameter) were placed in the right and left lung, respectively, in areas without pathologic abnormalities. For CT scans, additional measurements of HUs of pulmonary lesions and HUs of normal right and left lung parenchyma were performed.
Statistical Analysis
Statistical analysis was performed using the MedCalc software package (version 7.2.0.2., for Windows [Microsoft] ). Descriptive statistical evaluation was performed; differences in image quality and size of lung lesions were compared using a 2-sample Student t test. Differences were deemed to be significant at a P value of less than 0.05. In addition, the mean SUV mean and SUV max of PET/CT and PET/MR imaging were correlated (correlation coefficient R, P value, and 95% confidence interval [CI]), and a Bland-Altman plot was performed. To analyze the diagnostic performance of both modalities, the detection rate was calculated on the basis of the total lung lesions determined by the standard of reference.
RESULTS
Detection of Benign and Malignant Pulmonary Lesions
Forty-seven pulmonary nodules were present in 25 of 40 patients (n 5 14 . 1 cm, n 5 33 , 1 cm diameter) as seen in Table 2 . According to the standard of reference, 24 pulmonary lesions seen were categorized as malignant and 23 were categorized as benign. Dixon images detected 15 of 47 lung lesions (no false-positive findings), and VIBE images detected 32 of 47 lesions (3 lesions false-positive), respectively. The detection rates for small lung lesions less than 1 cm in diameter (n 5 33 in CT) on MR images were significantly lower, with a detection rate of 9 of 33 for the Dixon sequence and 15 of 33 for the VIBE sequence (P , 0.0001 for VIBE and Dixon sequence). The characterization of all lung lesions in CT, VIBE, and Dixon is shown in Table 3 . In CT, most of the lung lesions were categorized as most likely unspecific/benign or suggestive of malignancy, and only 2 of 47 lung lesions were classified as indeterminate. However, in the Dixon sequence 27% and in VIBE 22% of the lung lesions were classified as indeterminate.
Image Quality in CT, MR Imaging, and PET and Assessment of Lesion Size
The results of overall image quality (mean, SD, and P value) in CT, MR imaging, and PET are seen in Table 4 . As suspected, CT revealed the highest score, with an overall excellent image quality score of 3 in all datasets. There was a significantly lower image quality when comparing Dixon and VIBE sequences with CT whereas PET from PET/CT and PET from PET/MR imaging showed similar results.
There was no significant difference in size of pulmonary lesions between CT, compared with Dixon (P 5 0.1), and VIBE sequence, compared with CT (P 5 0.8). Furthermore, there was a strong correlation between the lesions size of CT and VIBE (R 5 0.97; P , 0.0001; 95% CI, 0.9307-0.9852) and between CT and Dixon sequence (R 5 0.55; P 5 0.0328; 95% CI, 0.0556-0.8297); detailed information with a graphical correlation analysis and a Bland-Altman plot can be seen in Supplemental Figure 1 (supplemental materials are available at http://jnm.snmjournals.org).
The m map of the lung was identified correctly in 35 of 40 patients.
Correlation Between SUVs from PET/CT and PET/MR Imaging
The PET datasets of PET/MR imaging and PET/CT revealed 22 of 47 pulmonary lesions with focal 18 F-FDG uptake in 10 of the 40 patients (21% of all lung lesions). In PET/MR imaging, mean SUV mean was 6.3 6 5.5 and mean SUV max was 9.2 6 8.3. Corresponding SUV mean and SUV max of PET/CT were 5.1 6 4.0 and 7.3 6 5.8, respectively. No statistical difference could be found between mean SUV CT and SUV MR (SUV of the PET of PET/CT and SUV of the PET of PET/MR imaging, respectively; P 5 0.388) as well as maximum SUV CT and SUV MR (P 5 0.362). Moreover, a high linear correlation coefficient in the SUV mean and SUV max for the PET images from PET/CT and PET/MR imaging was found, as shown in Figure 1 for SUV mean (correlation coefficient R 5 0.90; P , 0.0001; 95% CI, 0.77-0.96 for SUV mean , and R 5 0.91; P , 0.0001; 95% CI, 0.80-0.96 for SUV max ). Correlation analysis and Bland-Altman plot for SUV max and normal lung tissue can be found in Supplemental Figure 2 . Because there was tendency for higher SUVs in PET/MR imaging, we reconstructed the PET data of PET/MR imaging also using the HU of the normal lungs as determined by the corresponding CT of the same patient and not the fixed m value of 224 for lungs normally used in PET/MR imaging. This was done for 7 patients with 13 lesions. The mean values and SDs for SUV mean were 3.65 6 2.92. The corresponding values for PET/CT were 3.73 6 3.12 and for PET/MR imaging with fixed m value, 4.08 6 3.25.
Figures 2 shows representative images (CT, VIBE, and Dixon images as well as PET of PET/CT) of a patient with a small lung lesion in the left upper lung lobe with no suspected 18 F-FDG uptake. The lung lesion was seen in the CT and VIBE sequence but not in the Dixon sequence. Additional representative images are shown in the supplemental material.
DISCUSSION
The results of this study indicate that there is no significant difference between PET datasets of the lung in PET/MR imaging and PET/CT concerning image quality and lesion characterization. Adding a diagnostic MR imaging sequence for lung analysis in deep inspiration significantly increases the pulmonary lesion detection rate in PET/MR imaging; however, PET/MR imaging is still inferior to PET/CT for diagnostic CT of the lung.
Schwenzer et al. were the first, to our knowledge, to compare the performance of whole-body hybrid PET/MR imaging and PET/CT in patients with lung lesions; however, this study dealt with primary staging of lung cancer with rather large lesion sizes (8) . We focused on comparing the performance of PET/MR imaging and PET/CT for lung lesions in cancer patients in general, which is of importance because in this indication the lesions usually are substantially smaller and the requirements for imaging are different from those with primary staging of lung cancer. Most of the lung lesions in our patient population were smaller than 1 cm (33/47), which explains the lower detection rate in our study. For these small lesions, detection is especially difficult in MR imaging because of the low proton density of lung tissue and the limited spatial resolution (23) . A study comparing low-dose CT in shallow breathing and Dixon-based MR imaging (used for attenuation correction) of 18 F-FDG-positive and -negative pulmonary nodules in a trimodality PET/CT/MR setup showed similar detection rates and localization accuracy. In our study, the Dixon sequence for attenuation correction performed significantly worse and was inferior to both the CT and the dedicated contrast-enhanced T1-weighted VIBE sequence in inspiration (17, 24) . These discrepancies might, on the one hand, be explained by methodologic differences, because different systems and sequences were used. Also, we used diagnostic CT of the chest in deep inspiration as a standard of reference and not a CT in shallow breathing. The detection of lung lesions in CT not performed in deep inspiration might be hampered, especially at the base of the lungs because of suboptimal expansion of lung tissue, which might contribute to the better performance of CT in our study (16, 25) .
We also evaluated a dedicated contrast-enhanced T1-weighted VIBE sequence in inspiration for hybrid PET/MR imaging. When the detection rate of VIBE was compared with CT scan, 32 of 47 of the lung lesions were seen in VIBE as well; the ones that were not detected (n 5 15) were mostly lung lesions with a diameter less than 1 cm. Thus, for pulmonary diagnostic in MR imaging an additional imaging sequence (e.g., contrast-enhanced VIBE) is essential, although the diagnostic value of contrast-enhanced VIBE is still inferior to CT, especially for small lung lesions. However, the significance of this finding might vary depending on the specific clinical scenario. For some patient groups, the detection rate of the contrast-enhanced VIBE sequence might be sufficient, for example, in prostate cancer patients with early biochemical relapse, because in this group lung metastases are rare and when present usually they are larger than 1 cm (26) . Also many patients might already present with diagnostic CT images including the chest before undergoing the PET/MR examination. However, for most oncologic patients without prior CT of the chest, detection also of small lung nodules usually matters. Thus, we feel that a low-dose unenhanced CT of the lungs should be added to the PET/MR imaging in these cases, although future prospective studies finally have to define the value of PET/MR imaging, including dedicated sequences for lung imaging for specific oncologic indications.
In our study, we had 3 false-positive lung lesions in the VIBE sequence, compared with CT, meaning by our definition lesions seen in MR without any correlate in the respective CT scan. These false-positives were in 2 cases vascular structures in the lung periphery misinterpreted as nodules and in 1 case a lymph node in the paraaortal fat tissue of the thoracic aorta wrongly localized and thus misclassified as a lung nodule. In our experience the differential diagnosis of lesions seen in MR imaging was more difficult than in CT, as shown by the higher rate of indeterminate findings in MR imaging, compared with CT. In CT, characteristics such as the shape and density of a lesion and the imaging characteristics of the surrounding lung parenchyma might all help in differentiating malignant from benign lesions, for example, infectious infiltrates (27) . As a consequence, some 18 F-FDG-avid lesions with a correlate in MR imaging were wrongly classified as probably malignant in PET/MR imaging but were correctly classified in PET/CT by the CT information as probably infectious (benign), which was proven by follow-up imaging.
Concerning the quality of the PET component of PET/MR imaging versus PET/CT for lung lesions, we found a comparable image quality and detection rate for both systems in the qualitative comparison, with highly correlating SUVs in the quantitative analysis. This finding suggests that PET/MR imaging is robust for the assessment of lung lesions and comparable to PET/CT despite differences in detector technology and attenuation correction. It has to be stressed, however, that both scanners at the time of the study did not use time-of-flight (TOF) technology. It is known that TOF increases the performance of PET, especially for small structures (28) . Thus, the overall performance for 18 F-FDG PET is expected to improve also for detection of small lung lesions using TOF technology, which is, however, not available in the current PET/MR imaging system used here.
Contrary to previous studies focusing on lesions outside the lungs, we could see a tendency for slightly higher SUVs in PET/MR imaging, compared with PET/CT, which was not statistically significant (14) . One potential explanation might be that the m values from PET/CT for the lung were lower in the patients with lesions than the fixed value of 224 used in PET/MR imaging for lung tissue. We thus recalculated the m values for lung in PET/CT for a subset of patients with lung lesions based on the HUs measured in normal lung in these patients and reconstructed the PET data of PET/MR imaging of the patients with 18 F-FDG-avid lesions using the respective m values from CT. This resulted in lower SUVs in the newly reconstructed PET images from PET/MR imaging, which now were slightly lower than the PET/CT data, suggesting a tendency for overestimation of the true m values by the fixed value used in PET/MR imaging in our patient population. However, other factors might also play a role, such as surface coils or different scanner/ detector geometry. Also, biologic factors might contribute, such as a more pronounced trapping of tracer in malignant lesions due to the delayed imaging time point of PET/MR imaging; however, as mentioned before, the latter could not be observed for lesions outside the lung up to now in other comparative studies of PET/CT and PET/MR imaging with single-injection dual-imaging protocols. Our study had some limitations. For ethical reasons, no histopathology as the gold standard for pulmonary lesions could be provided. However, in our study we were mainly interested in the general performance of PET/MR imaging versus PET/CT in the detection of lung lesions and did not focus primarily on the classification of the lesions. Moreover, because of the time-consuming PET/CT and PET/MR imaging examination, the protocol in our study comprised only one additional diagnostic sequence for lung imaging (VIBE). It is known that the detection rate of MR imaging for small lung lesions can be improved using a multisequence protocol (17) . Thus, potential improvements can be expected by multisequence protocols also including respiratory triggering and gating of PET and MR data.
CONCLUSION
Our study shows that 18 F-FDG PET performance in PET/MR imaging for the assessment of lung lesions is robust and equivalent to PET/CT despite differences in detector technology and attenuationcorrection techniques. The detection rate of lung lesions can be significantly improved by adding a diagnostic contrast-enhanced VIBE sequence in inspiration to the PET/MR imaging protocol. However, the detection rate of small lung lesions is still inferior, compared with PET/CT with diagnostic CT of the chest.
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